No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 185 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Recognising the essential role of clinical research nurses October 13, 2021 Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical... May 27, 2025 Eflornithine Plus Sulindac Not Superior to Either Drug Alone in FAP September 15, 2020 No Improvement in OS or PFS from Sacituzumab Govitecan Compared with... March 24, 2025 Load more HOT NEWS Zilovertamab Vedotin Is Safe and Demonstrates Activity In Heavily Pretreated Patients... How TRACERx is helping us predict lung cancer’s next move Cancer in My Community: Working Toward Early Diagnosis for Children With... Trial Results Confirm Effectiveness of Atezolizumab Against a Rare Sarcoma
